Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer

Table 4 Baseline characteristics of the low-and high-enhancement groups

Variable	TRER ≤ 0.7, No. of patients, n (%)	TRER > 0.7, No. of patients, n (%)	P value
Age (yr)			0.397
≤ 60	22 (50.0)	9 (39.1)
> 60	22 (50.0)	14 (60.9)
Sex			0.170
Male	25 (56.8)	17 (73.9)
Female	19 (43.2)	6 (26.1)
Tumour location			0.117
Head/uncinate	26 (59.1)	18 (78.3)
Body/tail	18 (40.9)	5 (21.7)
CA19-9			0.230
< 37 ng/mL	11 (25.0)	9 (39.1)
≥ 37 ng/mL	33 (75.0)	14 (60.9)
AJCC stage (2017)			0.015
I	4 (9.1)	7 (30.4)
II	16 (36.4)	11 (47.8)
III	24 (54.5)	5 (21.7)
Tumour differentiation			0.634
Highly/moderately	33 (75.0)	16 (69.6)
Poorly/undifferentiated	11 (25.0)	7 (30.4)
Vascular invasion			0.071
No	30 (68.2)	21 (91.3)
Yes	14 (31.8)	2 (8.7)
Surgical margin			0.501
Negative	36 (81.8)	21 (91.3)
Positive	8 (18.2)	2 (8.7)
Adjuvant chemotherapy			0.087
No	25 (56.8)	8 (34.8)
Yes	19 (43.2)	15 (65.2)

CA19-9: Carbohydrate antigen 19-9; AJCC: American Joint Committee on Cancer; TRER: Tumour relative enhancement ratio.